Daratumumab Plus Bortezomib and Dex Improves PFS, ORR in Myeloma

Share this content:
Adding daratumumab to bortezomib and dexamethasone improved progression-free survival, overall response rate, and time to next treatment.
Adding daratumumab to bortezomib and dexamethasone improved progression-free survival, overall response rate, and time to next treatment.

Adding daratumumab to bortezomib and dexamethasone improved progression-free survival, overall response rate, and time to next treatment compared with bortezomib and dexamethasone alone among patients with relapsed or refractory multiple myeloma, according to an interim analysis presented at European Society for Medical Oncology (ESMO) 2016 Congress.1

Daratumumab is a human CD38-directed monoclonal antibody approved by the U.S. Food and Drug Administration as a single agent for heavily pretreated multiple myeloma. In the CASTOR study (ClinicalTrials.gov Identifier: NCT02136134), researchers evaluated the efficacy and safety of daratumumab in combination with bortezomib and dexamethasone.

Investigators enrolled 498 patients with multiple myeloma who had received at least 1 prior line of therapy. Of those, 76% had received prior treatment with an immunomodulatory agent, 66% had previously received bortezomib, and 48% had received both. Thirty-three percent were refractory to immunomodulatory treatment and 32% were refractory to the last line of therapy.

Participants were randomly assigned 1:1 to receive 8 cycles of bortezomib and dexamethasone with or without daratumumab until disease progression or unacceptable toxicity.

At a median follow-up of 7.4 months, results showed that daratumumab significantly reduced the risk of progression by 61% compared with bortezomib and dexamethasone alone (hazard ratio [HR], 0.39; 95% CI, 0.28-0.53; P < .0001).

The overall response rate was 83% with daratumumab versus 63% without (P < .0001), with 19% and 9% achieving complete responses or better (P = .0012). Daratumumab was associated with a 70% reduction in the time to next therapy compared with bortezomib and dexamethasone alone (HR, 0.30; 95% CI, 0.20-0.45; P < .0001).

Median overall survival was not yet reached for either treatment arm.

RELATED: Daratumumab May Be Effective Treatment for Relapsed or Refractory Myeloma

 

The safety profile of daratumumab, bortezomib, and dexamethasone is consistent with previous reports.

The findings suggest that this novel combination should be considered a new standard of care for patients with relapsed or refractory multiple myeloma receiving bortezomib and dexamethasone.                      

Reference

  1. Weisel K, Palumbo A, Chanan-Khan A, et al. Phase 3 randomised study of daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR. Paper presented at: European Society for Medical Oncology (ESMO) 2016 Congress; October 7-11, 2016; Copenhagen, Denmark.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters